PanCancer IO 360
Currently, evaluating immunotherapy responders from non-responders requires flow cytometry to analyze tumor immune Infiltrate. However, flow cytometry requires cells from fresh tissue, only a single sample can be sorted at a time, and the sorting process is slow. NanoString has created a novel gene expression panel to separate check point inhibitor responders from non-responders. The PanCancer IO 360 Gene Expression Panel is a 770-gene expression panel that combines vital components involved in the complex interplay between the tumor, microenvironment and immune response in cancer allowing for a multifaceted characterization of disease biology and interrogation of mechanisms of immune evasion.
There are several advantages of this panel over flow cytometry: 1) fresh tissue is not required, 2) you can conduct analysis on 12 samples at a time, 3) the analysis is fast, and 4) you receive a Tumor Infiltrating Lymphocyte (TIL) abundance score for each sample, making it easy to determine if your treatment had an effect on Tumor Infiltrating Lymphocytes (TILs)
Genes in panel
Published use of this panel
Ayers, Mark, et al. “IFN-y-related mRNA profile predicts clinical response to PD-1 blockade.” The Journal of Clinical Investigation 127.8 (2017).